How Metabolic Syndrome May Prime the Brain’s Immune Cells and Weaken Its Brakes Against Seizures

Scientists have long known that metabolic syndrome and epilepsy travel together more often than chance would predict. Large population studies have linked type 2 diabetes, obesity, and related metabolic abnormalities to an increased risk of new-onset epilepsy, while people with epilepsy show a higher prevalence of metabolic comorbidities than the general population. What has remained stubbornly unclear is how chronic peripheral metabolic stress—a condition that unfolds in blood vessels, fat tissue, and the gut—could be translated into a persistent, circuit-selective state of neuronal hyperexcitability inside the brain. Now, a hypothesis-driven framework published in Frontiers in Cellular Neuroscience proposes a unifying answer under a new name: immunometabolic synaptopathy.

The framework, developed by Baihui Zhang, Wenjin Wang, Tao Li, and Hua Huang of Chengdu University of Traditional Chinese Medicine and Dazhou Central Hospital, does not claim to have proven a complete causal chain. Instead, it assembles previously fragmented observations—epidemiological associations, blood–brain barrier studies, neuroimmune research, and cellular neuroscience—into a structured sequence of mechanistic nodes that can be experimentally tested, refined, or falsified. The authors are careful to distinguish well-supported biology from cross-context inference, and they explicitly state that the full pathway from metabolic syndrome to spontaneous epilepsy has not been demonstrated end-to-end.

At the heart of the proposal are three CNS interfaces through which peripheral metabolic and inflammatory signals might reach the brain. The first is the blood–brain barrier itself. Chronic hyperglycemia promotes the non-enzymatic glycation of proteins and lipids, generating advanced glycation end-products that bind to RAGE receptors on brain endothelial cells and activate NF-κB-dependent inflammatory signaling. This can reduce the expression or alter the localization of tight-junction proteins such as claudin-5, occludin, and zonula occludens-1, increasing paracellular permeability. Clinical data support the association: in a cohort of more than 1,000 individuals, diabetes was linked to an increased cerebrospinal fluid-to-plasma albumin quotient, a clinical marker of blood–CNS barrier dysfunction, and higher body mass index predicted subsequent increases in this quotient over long-term follow-up. Dyslipidemia adds a complementary route of injury, with saturated fatty acids activating TLR4 signaling in endothelial cells and oxidized low-density lipoprotein inducing mitochondrial dysfunction and impaired nitric oxide bioavailability.

Once barrier integrity is compromised, circulation-restricted molecules such as albumin can enter brain parenchyma, where albumin activates TGF-β/ALK5 signaling in astrocytes—a pathway previously implicated in epileptogenic network remodeling after blood–brain barrier dysfunction. But the framework argues that passive leakage alone cannot explain the persistence of CNS inflammation during chronic metabolic disease. That persistence, the authors propose, may depend on a second interface: the meningeal lymphatic–glymphatic–skull marrow axis. Functional lymphatic vessels along the dural sinuses drain CSF-derived solutes and immune cells toward deep cervical lymph nodes, while glymphatic transport exchanges CSF and interstitial fluid along perivascular spaces in a process dependent on aquaporin-4 polarization at astrocytic endfeet. Obesity, aging, vascular dysfunction, and sleep disruption have all been associated with impaired lymphatic drainage or reduced glymphatic transport, potentially prolonging the residence of cytokines and metabolic waste products within CNS border compartments.

The third component of this axis is the skull bone marrow. Direct vascular channels connecting cranial marrow to the dura have been identified as routes for myeloid-cell trafficking between skull marrow and CNS border tissues, allowing neutrophils and monocytes to reach the meninges without first entering the systemic circulation. Metabolic syndrome is associated with altered hematopoiesis and a myeloid-biased marrow phenotype, and recent evidence indicates bidirectional communication between CSF and skull marrow niches. The authors propose a coupled clearance–immune supply model: metabolic alterations may increase the availability of inflammatory myeloid cells while impaired lymphatic and glymphatic pathways prolong the residence of inflammatory mediators, together favoring a persistent meningeal and perivascular inflammatory niche capable of sustaining glial activation. Notably, this model does not require direct migration of skull marrow cells into brain parenchyma; border-resident immune cells could influence microglia and astrocytes indirectly through cytokines and vascular signaling.

The gut–brain axis supplies a third stream of recurrent signals. Obesity and insulin resistance alter microbial composition, intestinal barrier integrity, and metabolite production. Reduced abundance of butyrate-producing taxa such as Faecalibacterium and Roseburia may weaken anti-inflammatory short-chain fatty acid signaling, while impaired intestinal tight junctions permit translocation of bacterial lipopolysaccharide into the circulation—a state termed metabolic endotoxemia that activates TLR4-dependent signaling in monocytes, adipose tissue macrophages, and potentially CNS-associated immune cells. The therapeutic relevance of this axis is underscored by ketogenic diet studies in which microbiota transfer experiments suggest that part of the diet’s seizure protection can be transferred to recipient animals, although whether the same microbial pathways mediate the relationship between metabolic syndrome and spontaneous epileptogenesis remains uncertain.

These converging peripheral signals set the stage for the framework’s central immunological claim: trained-immunity-like microglial priming. Trained immunity refers to antigen-independent innate immune memory in which a primary stimulus induces sustained metabolic and epigenetic changes that enhance responses to later, unrelated challenges. The phenomenon is well characterized in peripheral monocytes exposed to β-glucan, BCG vaccination, oxidized lipoproteins, and Western-diet stimuli, involving a shift toward glycolysis via mTOR and HIF-1α, accumulation of immunoregulatory metabolites such as succinate and fumarate, epigenetic remodeling at inflammatory gene loci, and enhanced cytokine responses upon re-stimulation. A landmark study showed that systemic inflammation induces innate immune memory in the brain, accelerating amyloid pathology in Alzheimer’s models through microglial chromatin remodeling. Whether microglia in metabolic syndrome–associated epileptogenesis undergo canonical trained immunity remains unresolved, and the authors deliberately use the term trained-immunity-like microglial priming to denote a plausible state of persistent immunometabolic sensitization that requires experimental validation.

The framework generates falsifiable predictions: microglia isolated from metabolically stressed animals should retain altered glycolytic flux and mitochondrial reserve after peripheral normalization; chromatin profiling should reveal sustained enrichment of activating histone marks such as H3K4me3 and H3K27ac at inflammatory loci including IL-1β, TNF-α, and NLRP3; microglia should show exaggerated cytokine responses to standardized secondary stimulation after a recovery period; and pharmacological or genetic interruption of mTOR, HIF-1α, or NLRP3 during metabolic exposure should attenuate later recall responses and reduce seizure susceptibility. None of these predictions has yet been systematically validated in metabolic syndrome–associated epilepsy, but each is experimentally discriminable.

Alongside microglial priming, the framework posits astrocytic homeostatic failure—impaired glutamate uptake through EAAT1 and EAAT2, compromised potassium buffering through Kir4.1 channels, disturbed aquaporin-4 polarization, inadequate metabolic and trophic support, and extracellular-matrix dysregulation driven by matrix metalloproteinases. These glial alterations converge, the authors argue, on a specific circuit-level target: the parvalbumin-positive interneuron–perineuronal net unit. PV-positive fast-spiking interneurons provide powerful perisomatic inhibition to pyramidal neurons and are essential for gamma-frequency synchronization and network stability, but they operate within narrow energetic and ionic constraints. Their sustained high-frequency firing demands substantial mitochondrial capacity and Na⁺/K⁺-ATPase activity, and most are wrapped in perineuronal nets—extracellular-matrix structures composed of hyaluronan, chondroitin sulfate proteoglycans, and tenascin-R—that stabilize synapses and buffer oxidative stress. Six interacting stress pathways—bioenergetic substrate deprivation, oxidative stress that damages parvalbumin itself, loss of trophic support through BDNF/TrkB and neuregulin-1/ErbB4 signaling, extracellular potassium accumulation, glutamate excess, and proteolytic PNN remodeling—could jointly weaken PV-mediated inhibition and shift the excitation–inhibition balance toward hyperexcitability.

Finally, the authors nominate five candidate molecular hub nodes for mechanistic testing: NLRP3, mTOR, HIF-1α, MMP-9, and Kir4.1. Their translational readiness differs sharply. mTOR inhibition has direct clinical validation in tuberous sclerosis complex, where the Phase III EXIST-3 trial showed that everolimus reduced treatment-resistant focal-onset seizures, but that efficacy cannot be extrapolated to metabolically associated epileptogenesis. The CNS-penetrant NLRP3 inhibitor NT-0796 demonstrated CSF exposure and reductions in CSF IL-1β during a Phase 1b study in Parkinson disease, providing human evidence of CNS target engagement but no antiseizure efficacy data. Glyburide shows negligible penetration across the intact human blood–brain barrier, metformin acts pleiotropically rather than as a selective HIF-1α inhibitor, and available MMP-modulating drugs are nonspecific. The framework’s immediate value, the authors conclude, is experimental rather than clinical: it defines intervention points through which the hypothesis can be supported, refined, or falsified, while longitudinal, cell- and pathway-specific studies determine whether immunometabolic synaptopathy represents a genuine causal pathway, a susceptibility state relevant to selected patients, or a useful conceptual scaffold for organizing currently fragmented evidence.

Subject of Research: A hypothesis framework linking metabolic syndrome to epileptogenesis through CNS immune interface dysfunction, trained-immunity-like microglial priming, astrocytic homeostatic failure, and vulnerability of parvalbumin interneuron–perineuronal net units

Article Title: Immunometabolic synaptopathy: linking metabolic syndrome to epileptogenesis through trained immunity and parvalbumin interneuron vulnerability

Article References: Immunometabolic synaptopathy: linking metabolic syndrome to epileptogenesis through trained immunity and parvalbumin interneuron vulnerability. (n.d.). https://doi.org/10.3389/fncel.2026.1979155

Image Credits: AI Generated

DOI: 10.3389/fncel.2026.1979155

Keywords: immunometabolic synaptopathy, metabolic syndrome, epileptogenesis, trained immunity, microglial priming, parvalbumin interneurons, perineuronal nets, blood–brain barrier, astrocytes, NLRP3 inflammasome, mTOR signaling, gut–brain axis